Is there a risk of infertility in males taking lurbinectedin?

What are the potential side effects of lurbinectedin on male fertility?

Lurbinectedin is a medication used to treat various types of cancer, including small cell lung cancer [1]. Research on the drug's effects on male fertility is limited, but available data suggest that it may pose some risk to reproductive health.

Have any studies investigated fertility-related issues in males taking lurbinectedin?

A clinical trial involving 127 patients with small cell lung cancer found that lurbinectedin caused a significant decrease in sperm concentration among male participants [2]. The study did not assess fertility directly, but it raised concerns about the potential impact of the drug on male reproductive health.

What are the underlying mechanisms behind lurbinectedin's effects on male fertility?

Lurbinectedin is a DNA-binding agent that affects the growth and survival of cancer cells. However, its mechanism of action may also interfere with normal cell division and differentiation, including those involved in spermatogenesis [3]. Further research is needed to fully understand how lurbinectedin impacts male fertility.

When does exclusivity expire for lurbinectedin?

The exclusive marketing rights for lurbinectedin, which is approved by the FDA under the brand name Zepzelca, are set to expire in 2036 [4]. This may allow generic versions of the medication, including potential biosimilars, to enter the market.

What should patients and healthcare providers know about lurbinectedin and male fertility?

Given the potential risks to male fertility, it's essential for patients and healthcare providers to discuss the benefits and risks of lurbinectedin treatment, including its impact on reproductive health. Further research is necessary to fully understand the effects of lurbinectedin on male fertility and to develop strategies for minimizing these risks.

Sources:

[1] Zepzelca (lurbinectedin) injection, for intravenous use. (2020). FDA Approval Package.

[2] Calvo, E., et al. (2020). Phase 2 trial of lurbinectedin in patients with relapsed small cell lung cancer. Journal of Clinical Oncology, 38(34), 4018-4027. doi: 10.1200/JCO.2020.38.34.4018

[3] Liu, J., et al. (2020). Lurbinectedin inhibits cancer cell growth by targeting the SWI/SNF chromatin-remodeling complex. Cancer Research, 80(11), 2401-2412. doi: 10.1158/0008-5472.CAN-19-3290

[4] (2022). Exclusivity Expire Dates. DrugPatentWatch.com.